We would love to hear your thoughts about our site and services, please take our survey here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksN4 Pharma Plc Share News (N4P)

Share Price Information for N4 Pharma Plc (N4P)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 0.80
Bid: 0.75
Ask: 0.85
Change: 0.00 (0.00%)
Spread: 0.10 (13.333%)
Open: 0.80
High: 0.00
Low: 0.00
Prev. Close: 0.80
N4P Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

AIM WINNERS & LOSERS: FireAngel 2023 earnings below expectations

Tue, 25th Apr 2023 10:30

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Tuesday.

----------

AIM - WINNERS

----------

Eckoh PLC, up 16% at 37.80 pence, 12-month range 30.00p-46.00p. The secure payment and customer contact products firm expects revenue and adjusted profit in the year ended March 31 to be "significantly" ahead of the previous year. Revenue is seen at GBP39 million, up from GBP31.8 million a year prior, while adjusted operating profit is seen at GBP7.6 million, up from GBP5.2 million. According to Eckoh, market consensus is for full-year revenue to be GBP40.3 million and adjusted operating profit to be GBP7.5 million. Notes "excellent" progress in its "key" North American region, as well as growth in its total contracted business of more than 50% during the financial year. Expects to announce its full-year results on June 14.

----------

N4 Pharma PLC, up 16% at 2.20 pence, 12-month range 1.50p-3.98p. The specialist pharmaceutical company provides an update on its ongoing in vitro siRNA research work. Completes work on establishing assays to measure how Nuvec loaded with BCL-2 siRNA can silence expression of the BCL-2 protein. Nuvec is N4's delivery system for cancer treatments and vaccines. BCL-2 is a form of protein that regulates cell death in healthy cells, however, diverging expression can facilitate tumour development and resistance to cancer therapy. Says studies so far have demonstrated that the maximum inhibition of cell growth by SiRNA to either EGFR or BCL-2 loaded on Nuvec was comparable to that produced by two commercially available small molecule drugs, Gefitinib for EGFR and Venetoclax for BCL-2. Further work is planned to assess the minimal loading of siRNA on Nuvec to achieve comparable inhibition to the two commercially available drugs.

----------

AIM - LOSERS

----------

FireAngel Safety Technology Group PLC, down 27% at 8.25 pence, 12-month range 7.20p-17.25p. The home safety product developer says that trading in the year-to-date has been in-line with the company's expectations. Notes two exceptions to this, but says the effect of those exceptions is partly mitigated by lower than expected costs. Notes supply chain issues impacted the company throughout 2022, causing lower production than planned and leading to restricted or intermittent supply to its customers. Consequently, these issues have led to a loss of momentum of the company. Says restoring this momentum may take the rest of 2023 to achieve. Further, notes that only one of two significant contacts expected to contribute to the first quarter of 2023 has been secured to date. This will lead to slightly lower revenues than forecast in 2023, FireAngel says. Company also expects earnings before interest, tax, depreciation and amortisation for 2023 to be "materially below market expectations".

----------

Strategic Minerals PLC, down 24% at 0.19 pence, 12-month range 0.13p-0.45p. The producer and explorer posts revenue of USD415,000 in the first quarter of 2023, down from USD663,000 the previous year. Says this reflects the anticipated reduced demand from some customer amid a dip in economic activity in the US. Explains that increased mining costs and negative market sentiment has impacted proposed debt-based funding for the restart of production at the Leigh Creek copper mine. Strategic Minerals says: "Slower US economic growth continues to impact demand for the magnetite product provided at Cobre in New Mexico, US. While sales to the company's "fertilizer" customers appear somewhat unaffected, sales to "cement" customers have been notably impacted with the company's largest client continuing to suspend purchases whilst it runs down its existing stockpile. The reduction in demand has been partially offset by the 20% price increase in July 2022."

----------

By Heather Rydings, Alliance News senior economics reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.

More News
25 Apr 2024 11:56

N4 Pharma strikes partnership deal for intracellular delivery

(Alliance News) - N4 Pharma PLC on Thursday said it has entered into a collaboration agreement with SRI International Inc.

Read more
23 Apr 2024 13:32

IN BRIEF: N4 Pharma loss widens but "great optimism" remains

N4 Pharma PLC - Derbyshire, England-based pharmaceutical company focused on the development of Nuvec - Posts revenue of GBP1,953 in 2023, compared to no revenue a year ago. Pretax loss widens to GBP1.4 million from GBP1.2 million. Looks ahead to the rest of 2024 with "great optimism."

Read more
18 Apr 2024 12:14

N4 Pharma sees potential in Nuvec delivery method for cancer treatment

(Alliance News) - N4 Pharma PLC on Thursday reported that its novel delivery system for cancer treatment has shown promise, after a successful trial.

Read more
15 Feb 2024 13:17

N4 Pharma shares jump on latest Nuvec developments

(Sharecast News) - N4 Pharma announced a significant advancement in the development of Nuvec, an innovative delivery system tailored for cancer treatments, gene therapy, and vaccines, on Thursday.

Read more
15 Feb 2024 12:06

IN BRIEF: N4 Pharma shares rise on "encouraging" Nuvec research

N4 Pharma PLC - Derbyshire, England-based pharmaceutical company, focused on the development of Nuvec - Reports an "encouraging" update from its Nuvec delivery system for cancer treatments, gene therapy and vaccines. It has completed in-vitro experiments combining epidermal growth factor receptor and polo like kinase 1 molecules onto a Nuvec nanoparticle, before testing it on lung cancer cells. "The work clearly shows that there is a strong beneficial effect at 48 hours on cellular inhibition compared to single dose siRNA, by combining both EGFR and PLK1 onto the same particle," N4 says.

Read more
15 Feb 2024 10:52

AIM WINNERS & LOSERS: DSW warns on earnings amid tepid M&A markets

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Thursday.

Read more
19 Jan 2024 13:00

N4 Pharma's Nuvec granted patent in India

(Sharecast News) - N4 Pharma, a pharmaceutical company developing the cancer vaccine delivery system Nuvec, announced on Friday that it has received confirmation from the University of Queensland regarding the granting of its patent for Nuvec in India.

Read more
19 Jan 2024 09:26

IN BRIEF: N4 Pharma gets India patent for medical delivery system

N4 Pharma PLC - Derbyshire, England-based pharmaceutical company, focused on the development of Nuvec - University of Queensland has informed the company that it has been notified by its Indian patent attorney of the granting of its patent for Nuvec in India. Nuvec is a novel silica nanoparticle delivery system for cancer treatments, gene therapy and vaccines. N4 Pharma says the granted patent in India is for a composition of matter patent for the particle itself, alongside the manufacturing process relating to how the particle is made. Says it matches the patents granted in the US, Canada, Europe, Japan, Australia and China.

Read more
16 Jan 2024 14:05

N4 Pharma subsidiary agrees work programme for glaucoma treatment

(Sharecast News) - N4 Pharma announced a significant development through its subsidiary Nanogenics on Tuesday, after Nanogenics inked a contract to initiate the formulation and sequence selection work for its ECP105 product, aimed at pre-clinical studies at King's College, London.

Read more
16 Jan 2024 13:26

IN BRIEF: N4 Pharma touts contract to test glaucoma treatment, ECP105

N4 Pharma PLC - Derbyshire, England-based pharmaceutical company, focused on the development of Nuvec, a novel silica nanoparticle delivery system, for vaccines and therapeutics - Says subsidiary, Nanogenics Ltd, has signed a contract to start the formulation and sequence selection work to prepare its ECP105 product for testing in pre-clinical studies at King's College, London.

Read more
8 Jan 2024 12:30

N4 Pharma reports progress in Nuvec clinical research

(Sharecast News) - Pharmaceutical delivery system developer N4 Pharma reported significant progress in its research efforts to enhance viral vector performance using Nuvec on Monday.

Read more
8 Jan 2024 09:11

N4 Pharma hails increased efficacy of Nuvec when complexed with AAV8

(Alliance News) - N4 Pharma PLC on Monday said that a series of experiments have shown that Nuvec can deliver increased transduction efficacy, when complexed with Adeno-Associated virus 8.

Read more
18 Dec 2023 16:55

LONDON MARKET CLOSE: FTSE 100 outperforms European peers

(Alliance News) - Stock prices in London closed higher on Monday, after investors shrugged off hawkish comments from US Federal Reserve officials amid festive cheer.

Read more
18 Dec 2023 12:43

N4 Pharma rises on successful results from Nuvec administration

(Alliance News) - N4 Pharma PLC on Monday announced the successful oral administration of Nuvec with a DNA plasmid after receiving promising results from its research programme with the University of Queensland.

Read more
18 Dec 2023 11:17

N4 Pharma upbeat on recent Nuvec developments

(Sharecast News) - N4 Pharma updated the market on Monday on its ongoing research efforts related to Nuvec, its delivery system designed for cancer treatments and vaccines.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.